<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01148836</url>
  </required_header>
  <id_info>
    <org_study_id>08-497</org_study_id>
    <nct_id>NCT01148836</nct_id>
  </id_info>
  <brief_title>Coenzyme Q-10 and Pulmonary Arterial Hypertension</brief_title>
  <official_title>Coenzyme Q-10 in the Treatment of Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of Coenzyme Q-10, an antioxidant, in the
      treatment of pulmonary hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Abnormalities in the blood vessels in the lung are the hallmark of pulmonary hypertension.
      Links between increased free radical production, mitochondrial dysfunction and pulmonary
      hypertension have been studied but are poorly understood. The mitochondria of cells is the
      location where cellular energy is created and free radicals are atoms or groups of atoms with
      an odd (unpaired) number of electrons and can be formed when oxygen interacts with certain
      molecules. Once formed these reactive radicals can start a chain reaction, like dominoes.
      Their chief danger comes from the damage they can do when they react with important cellular
      components. Cells may function poorly or die if this occurs. The body produces free radicals
      in the normal course of energy production and in pulmonary hypertension, free radical
      production is found to be increased. To prevent free radical damage the body has a defense
      system of antioxidants. Coenzyme Q-10 is an antioxidant and it helps to protect cells from
      damage caused by the body's own free radicals. By providing oral supplementation of coenzyme
      Q-10, free radical levels will be decreased and cellular functioning in the pulmonary blood
      vessels may improve and even return to near normal functioning.

      The purpose of this study is to evaluate the effects of coenzyme Q-10, an antioxidant, in the
      treatment of pulmonary hypertension. We will assess coenzyme Q-10 supplementation in the
      treatment of pulmonary hypertension by clinical measurements and blood levels of certain
      cellular components. We would like to assess the effects of coenzyme Q-10 on the pulmonary
      vessels by measuring the lung diffusing capacity (a breathing test) and exhaled Nitric Oxide
      (NO) (a substance in the body that relaxes or dilates blood vessels). We will also measure
      endothelial progenitor cells (cells from the bone marrow) from a blood sample; these cells
      are markers of measure of blood vessel formation and repair. We will also measure the
      activity of superoxide dismutase (a protein in cells that executes the breakdown of a free
      radical into oxygen and hydrogen peroxide) in the blood. In addition, we will measure levels
      of coenzyme Q-10 in the blood. Other markers of disease response to therapy will be done
      including physical exam, BNP level (a blood marker that correlates with heart function),
      6-minute walk and echocardiography (ultrasound of the heart). A total of 60ml (5 tablespoons)
      of blood will be drawn at each visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left Ventricular End Diastolic Volume</measure>
    <time_frame>before and after three months of CoQ</time_frame>
    <description>Amount of blood in ventricle at end of diastole</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Right Ventricular Outflow</measure>
    <time_frame>before and after three months of CoQ</time_frame>
    <description>Velocity time interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Right Ventricle Myocardial Performance</measure>
    <time_frame>before and after three months of CoQ</time_frame>
    <description>Tei Index=(IRT+ICT)/ET, where IRT is isovolumic</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tricuspid Regurgitation Grade</measure>
    <time_frame>before and after three months of CoQ</time_frame>
    <description>Tricuspid Regurgitation Grade ranges from 1 (normal) to 4 (severe regurgitation)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Right Atrial Pressure</measure>
    <time_frame>before and after three months of CoQ</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Red Blood Cells</measure>
    <time_frame>before and after three months of CoQ</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>before and after three months of CoQ</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematocrit</measure>
    <time_frame>before and after three months of CoQ</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Corpuscular Hemoglobin</measure>
    <time_frame>before and after three months of CoQ</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red Blood Cell Distribution Width</measure>
    <time_frame>before and after three months of CoQ</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Coenzyme Q 10 and Pulmonary Hypertension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PAH subjects to take Co-Q daily for three months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Coenzyme Q 10 and Normal Controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Normal controls to take Co-Q daily for three months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Coenzyme Q-10 in Pulmonary Hypertension subjects</intervention_name>
    <description>Take 100mg Co-Q for three times daily</description>
    <arm_group_label>Coenzyme Q 10 and Pulmonary Hypertension</arm_group_label>
    <other_name>Coenzyme Q: Nutritional Supplement</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Coenzyme Q-10 in Normal Control subjects</intervention_name>
    <description>Take 100mg Co-Q for three times daily</description>
    <arm_group_label>Coenzyme Q 10 and Normal Controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and Females age equal to or greater than 18 not to exceed 65.

          -  Patients with PAH Class 1 (Venice 2003)

          -  PAH medications must not have changed for the last two months.

          -  Women of child-bearing age must use a double-barrier local contraception until
             completion of study.

          -  Subjects must demonstrate understanding of study and sign informed consent and have a
             reliable method of communication for contact and the ability to comply with the study
             requirements.

        Exclusion Criteria:

          -  Participation in any other studies at the time of enrollment

          -  History of any significant illness within four weeks of starting Coenzyme Q-10

          -  Hepatic insufficiency (transaminase levels &gt;4 fold the upper limit of normal or
             bilirubin &gt;2 fold the upper limit of normal).

          -  Renal insufficiency (creatinine &gt;2)

          -  Pregnancy,breast-feeding or lack of safe contraception.

          -  Acute heart failure

          -  Known allergy to the study drug or drugs similar to the study drug

          -  History of drug or alcohol abuse within last 12 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jackie Sharp, CNP</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2010</study_first_submitted>
  <study_first_submitted_qc>June 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2010</study_first_posted>
  <results_first_submitted>February 5, 2015</results_first_submitted>
  <results_first_submitted_qc>March 19, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 20, 2015</results_first_posted>
  <last_update_submitted>March 19, 2015</last_update_submitted>
  <last_update_submitted_qc>March 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Jacqueline Sharp</investigator_full_name>
    <investigator_title>Nurse Practitioner</investigator_title>
  </responsible_party>
  <keyword>Coenzyme Q-10</keyword>
  <keyword>Pulmonary Arterial Hypertension</keyword>
  <keyword>Pulmonary Arterial Hypertension Class I (Venice 2003)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coenzyme Q10</mesh_term>
    <mesh_term>Ubiquinone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Healthy Controls</title>
        </group>
        <group group_id="P2">
          <title>Pulmonary Hypertension Subjects (Disease)</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8">Enrollment completed</participants>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7">Enrollment completed</participants>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Healthy Controls Subjects</title>
        </group>
        <group group_id="B2">
          <title>Pulmonary Hypertension Subjects</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42" spread="5"/>
                    <measurement group_id="B2" value="41" spread="3"/>
                    <measurement group_id="B3" value="41.5" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Left Ventricular End Diastolic Volume</title>
        <description>Amount of blood in ventricle at end of diastole</description>
        <time_frame>before and after three months of CoQ</time_frame>
        <population>Due to financial constraints only PAH subjects had echocardiograms performed before and after Co-Q</population>
        <group_list>
          <group group_id="O1">
            <title>Pulmonary Hypertension Subjects</title>
            <description>Pulmonary Hypertension subjects taking Co-Q for three months</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular End Diastolic Volume</title>
          <description>Amount of blood in ventricle at end of diastole</description>
          <population>Due to financial constraints only PAH subjects had echocardiograms performed before and after Co-Q</population>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Co-Q</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Co-Q</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Right Ventricular Outflow</title>
        <description>Velocity time interval</description>
        <time_frame>before and after three months of CoQ</time_frame>
        <population>Due to financial constraints only PAH subjects had echocardiograms performed before and after Co-Q</population>
        <group_list>
          <group group_id="O1">
            <title>Pulmonary Hypertension Subjects</title>
            <description>Pulmonary Hypertension subjects taking Co-Q for three months</description>
          </group>
        </group_list>
        <measure>
          <title>Right Ventricular Outflow</title>
          <description>Velocity time interval</description>
          <population>Due to financial constraints only PAH subjects had echocardiograms performed before and after Co-Q</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Co-Q</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Co-Q</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Right Ventricle Myocardial Performance</title>
        <description>Tei Index=(IRT+ICT)/ET, where IRT is isovolumic</description>
        <time_frame>before and after three months of CoQ</time_frame>
        <population>Due to financial constraints only PAH subjects had echocardiograms performed before and after Co-Q</population>
        <group_list>
          <group group_id="O1">
            <title>Pulmonary Hypertension Subjects</title>
            <description>Pulmonary Hypertension subjects taking Co-Q for three months</description>
          </group>
        </group_list>
        <measure>
          <title>Right Ventricle Myocardial Performance</title>
          <description>Tei Index=(IRT+ICT)/ET, where IRT is isovolumic</description>
          <population>Due to financial constraints only PAH subjects had echocardiograms performed before and after Co-Q</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Co-Q</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Co-Q</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tricuspid Regurgitation Grade</title>
        <description>Tricuspid Regurgitation Grade ranges from 1 (normal) to 4 (severe regurgitation)</description>
        <time_frame>before and after three months of CoQ</time_frame>
        <population>Due to financial constraints only PAH subjects had echocardiograms performed before and after Co-Q</population>
        <group_list>
          <group group_id="O1">
            <title>Pulmonary Hypertension Subjects</title>
            <description>Pulmonary Hypertension subjects taking Co-Q for three months</description>
          </group>
        </group_list>
        <measure>
          <title>Tricuspid Regurgitation Grade</title>
          <description>Tricuspid Regurgitation Grade ranges from 1 (normal) to 4 (severe regurgitation)</description>
          <population>Due to financial constraints only PAH subjects had echocardiograms performed before and after Co-Q</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Co-Q</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Co-Q</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Right Atrial Pressure</title>
        <time_frame>before and after three months of CoQ</time_frame>
        <population>Due to financial constraints only PAH subjects had echocardiograms performed before and after Co-Q</population>
        <group_list>
          <group group_id="O1">
            <title>Pulmonary Hypertension Subjects</title>
            <description>Pulmonary Hypertension subjects taking Co-Q for three months</description>
          </group>
        </group_list>
        <measure>
          <title>Right Atrial Pressure</title>
          <population>Due to financial constraints only PAH subjects had echocardiograms performed before and after Co-Q</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Co-Q</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Co-Q</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Red Blood Cells</title>
        <time_frame>before and after three months of CoQ</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pulmonary Hypertension Subjects</title>
            <description>Pulmonary Hypertension subjects taking Co-Q for three months</description>
          </group>
          <group group_id="O2">
            <title>Normal Controls</title>
            <description>Normal controls taking Co-Q for three months</description>
          </group>
        </group_list>
        <measure>
          <title>Red Blood Cells</title>
          <units>10^6 cells/Âµl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Co-Q</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="0.2"/>
                    <measurement group_id="O2" value="4.5" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Co-Q</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="0.2"/>
                    <measurement group_id="O2" value="4.3" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemoglobin</title>
        <time_frame>before and after three months of CoQ</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pulmonary Hypertension Subjects</title>
            <description>Pulmonary Hypertension subjects taking Co-Q for three months</description>
          </group>
          <group group_id="O2">
            <title>Normal Controls</title>
            <description>Normal controls taking Co-Q for three months</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin</title>
          <units>g/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Co-Q</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" spread="0.9"/>
                    <measurement group_id="O2" value="13.3" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Co-Q</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" spread="0.8"/>
                    <measurement group_id="O2" value="12.9" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hematocrit</title>
        <time_frame>before and after three months of CoQ</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pulmonary Hypertension Subjects</title>
            <description>Pulmonary Hypertension subjects taking Co-Q for three months</description>
          </group>
          <group group_id="O2">
            <title>Normal Controls</title>
            <description>Normal controls taking Co-Q for three months</description>
          </group>
        </group_list>
        <measure>
          <title>Hematocrit</title>
          <units>% of red blood cell</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Co-Q</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.0" spread="2.1"/>
                    <measurement group_id="O2" value="39.9" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Co-Q</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.8" spread="1.8"/>
                    <measurement group_id="O2" value="38.6" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Corpuscular Hemoglobin</title>
        <time_frame>before and after three months of CoQ</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pulmonary Hypertension Subjects</title>
            <description>Pulmonary Hypertension subjects taking Co-Q for three months</description>
          </group>
          <group group_id="O2">
            <title>Normal Controls</title>
            <description>Normal controls taking Co-Q for three months</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Corpuscular Hemoglobin</title>
          <units>pg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Co-Q</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.8" spread="1.1"/>
                    <measurement group_id="O2" value="29.9" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Co-Q</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8" spread="1.0"/>
                    <measurement group_id="O2" value="29.9" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Red Blood Cell Distribution Width</title>
        <time_frame>before and after three months of CoQ</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pulmonary Hypertension Subjects</title>
            <description>Pulmonary Hypertension subjects taking Co-Q for three months</description>
          </group>
          <group group_id="O2">
            <title>Normal Controls</title>
            <description>Normal controls taking Co-Q for three months</description>
          </group>
        </group_list>
        <measure>
          <title>Red Blood Cell Distribution Width</title>
          <units>percentage of sizes of red blood cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Co-Q</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" spread="0.6"/>
                    <measurement group_id="O2" value="12.9" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Co-Q</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" spread="0.5"/>
                    <measurement group_id="O2" value="12.9" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The adverse event data was collected over each participants treatment period, up to three months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Coenzyme Q and Pulmonary Hypertension</title>
          <description>Pulmonary Hypertension subjects Nutritional Supplement Coenzyme Q-10: Nutritional Supplement</description>
        </group>
        <group group_id="E2">
          <title>Coenzyme Q and Healthy Controls</title>
          <description>Healthy Control subjects Nutritional Supplement Coenzyme Q-10: Nutritional Supplement</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Patient experienced nausea when taking Co-Q</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Length of the trial and number of subjects enrolled were both study limitations.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jacqueline Sharp, CNP</name_or_title>
      <organization>Cleveland Clinic</organization>
      <phone>216-636-0000</phone>
      <email>pylej@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

